CA3129024A1 - Use of vibegron to treat overactive bladder - Google Patents

Use of vibegron to treat overactive bladder Download PDF

Info

Publication number
CA3129024A1
CA3129024A1 CA3129024A CA3129024A CA3129024A1 CA 3129024 A1 CA3129024 A1 CA 3129024A1 CA 3129024 A CA3129024 A CA 3129024A CA 3129024 A CA3129024 A CA 3129024A CA 3129024 A1 CA3129024 A1 CA 3129024A1
Authority
CA
Canada
Prior art keywords
subject
vibegron
placebo
treatment
mean
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3129024A
Other languages
English (en)
French (fr)
Inventor
JR. Paul N. MUDD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urovant Sciences GmbH
Original Assignee
Urovant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urovant Sciences GmbH filed Critical Urovant Sciences GmbH
Publication of CA3129024A1 publication Critical patent/CA3129024A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3129024A 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder Pending CA3129024A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962820230P 2019-03-18 2019-03-18
US62/820,230 2019-03-18
US201962830302P 2019-04-05 2019-04-05
US62/830,302 2019-04-05
US201962842435P 2019-05-02 2019-05-02
US62/842,435 2019-05-02
US201962885767P 2019-08-12 2019-08-12
US62/885,767 2019-08-12
US201962897019P 2019-09-06 2019-09-06
US62/897,019 2019-09-06
US201962904429P 2019-09-23 2019-09-23
US62/904,429 2019-09-23
PCT/IB2020/052484 WO2020188505A1 (en) 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder

Publications (1)

Publication Number Publication Date
CA3129024A1 true CA3129024A1 (en) 2020-09-24

Family

ID=70166082

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3129024A Pending CA3129024A1 (en) 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder

Country Status (14)

Country Link
US (1) US20230027066A1 (https=)
EP (1) EP3941473A1 (https=)
JP (2) JP2022524576A (https=)
KR (2) KR20210142004A (https=)
CN (2) CN121489955A (https=)
AU (2) AU2020243514A1 (https=)
BR (1) BR112021017198A2 (https=)
CA (1) CA3129024A1 (https=)
IL (1) IL285910A (https=)
MX (1) MX2021009488A (https=)
PH (1) PH12021551975A1 (https=)
SG (1) SG11202108810YA (https=)
TW (2) TW202102221A (https=)
WO (1) WO2020188505A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634420A1 (en) 2017-06-06 2020-04-15 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
SG11202103662VA (en) 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
TW202245781A (zh) * 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍（ｖｉｂｅｇｒｏｎ）治療心臟衰竭之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
RS59402B1 (sr) 2013-03-15 2019-11-29 Merck Sharp & Dohme Postupak za pripremu beta 3 agonista i međuproizvoda
JP6197971B1 (ja) * 2016-04-22 2017-09-20 小野薬品工業株式会社 Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
US20170348288A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
US10057209B2 (en) * 2016-07-28 2018-08-21 Qualcomm Incorporated Time-sequenced multi-device address assignment
JP7670461B2 (ja) * 2017-06-06 2025-04-30 ウロバント サイエンシズ ゲゼルシャフト ミット ベシュレンクター ハフトゥング 過活動膀胱の治療のためのビベグロンの投薬
EP3634420A1 (en) * 2017-06-06 2020-04-15 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
EP3583905A1 (en) * 2018-06-20 2019-12-25 Arthrex Inc Percutaneous targeting device

Also Published As

Publication number Publication date
CN113840607A (zh) 2021-12-24
SG11202108810YA (en) 2021-10-28
AU2020243514A1 (en) 2021-08-26
AU2025256180A1 (en) 2025-11-13
MX2021009488A (es) 2021-09-21
TW202506129A (zh) 2025-02-16
WO2020188505A1 (en) 2020-09-24
CN121489955A (zh) 2026-02-10
JP2022524576A (ja) 2022-05-09
EP3941473A1 (en) 2022-01-26
JP2025084777A (ja) 2025-06-03
BR112021017198A2 (pt) 2021-11-16
TW202102221A (zh) 2021-01-16
PH12021551975A1 (en) 2022-07-04
IL285910A (en) 2021-10-31
KR20210142004A (ko) 2021-11-23
KR20260049872A (ko) 2026-04-14
US20230027066A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
AU2025256180A1 (en) Use Of Vibegron To Treat Overactive Bladder
McKeage Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms
JP7670461B2 (ja) 過活動膀胱の治療のためのビベグロンの投薬
JP2025032143A (ja) 良性前立腺肥大症の男性の過活動膀胱症状を治療するためのビベグロンの使用
EP4142729A1 (en) Methods of treating agitation associated with alzheimer's disease
US8901177B2 (en) Method of treating bladder disorders
AU2022376278A1 (en) Methods of treating agitation associated with alzheimer's disease
WO2004096141A2 (en) Method for promoting uninterrupted sleep by administration of trospium chloride
HK40126413A (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
EA052961B1 (ru) Вибегрон для лечения симптомов гиперактивного мочевого пузыря
US20250375417A1 (en) Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1)
US20240358692A1 (en) Treatment of scleroderma
BR122024021845A2 (pt) Usos de vibegron para tratar sintomas de bexiga hiperativa e reduzir ou diminuir as micções
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
Ellsworth Pharmacotherapy Update on the Treatment of Overactive Bladder Syndrome: Focus on Fesoterodine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220825

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20250225

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250225

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250228

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250314

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250314

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250314

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B11-B206 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: WITHDRAWAL REQUEST RECEIVED

Effective date: 20250709

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250711

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: T-6-6-B10-B11-B207 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: WITHDRAWN

Effective date: 20251210